Screener
Tyra Biosciences, Inc. TYRA Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest and other income, net | 2,693 | 3,703 |
| Total other income | 2,693 | 3,703 |
| Net loss | (39,305) | (28,147) |
| Unrealized loss on marketable securities, net | (286) | (82) |
| Comprehensive loss | $(39,591) | $(28,229) |
| Net loss per share, basic and diluted | $(0.64) | $(0.47) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 61,746,050 | 59,336,550 |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Tyra Biosciences, Inc. (TYRA) reported comprehensive income (loss), net of tax, attributable to parent of -$39.59M in Q1 2026.
- How has Tyra Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Tyra Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 40.2% year-over-year, from -$28.23M to -$39.59M.
- What is the long-term trend for Tyra Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2022 to 2025), Tyra Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 29.6% compound annual growth rate (CAGR), from -$55.33M to -$120.32M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity of a company during a period resulting from transactions and other events from non-owner sources. It encompasses net income as well as other items that bypass the income statement, such as unrealized gains or losses on available-for-sale securities or foreign currency translation adjustments. For a clinical-stage biotechnology company, it serves as a comprehensive measure of the overall financial performance and changes in net assets beyond standard operating results.
Ask your AI about Tyra Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude